NP与EP方案治疗非小细胞肺癌的近期疗效观察  

The Short Outcome of NVB Plus DDP Regimen and Ep Regimen in the Treatment of Non-small Cell Lung Cancer.

作　　者：曹凤军[1] 陈平[1] 汤翠菊[1] 李林均[1] 魏娟[1] 

机构地区：[1]十堰市人民医院肿瘤中心,湖北十堰442000

出　　处：《肿瘤防治杂志》2001年第3期287-289,共3页China Journal of Cancer Prevention and Treatment

摘　　要：目的 :比较NP(NVB +DDP)与EP(DDP +Vp 16 )方案治疗晚期非小细胞肺癌 (NSCLC)的近期疗效与不良反应。方法 :通过前瞻性对照研究 ,将 72例初治的中晚期NSCLC随机分为治疗组和对照组 ,分别给以NP与EP方案化疗 2个周期 ,按WHO标准评定疗效和不良反应。结果 :两组有效率 (CR+PR)各为 50 0 %和 2 7 8%。治疗组高于对照组 (P <0 0 5) ,全身状况治疗组也有明显改善 (P <0 0 5)。不良反应主要表现为骨髓抑制和静脉炎 ,重度白细胞下降和静脉炎发生率各为 55 6 %和2 5 0 %及 16 7%和 9 1% ,治疗组重于对照组 (P <0 0 5)。结论 :NVB +DDP是一种安全有效的化疗方案 ,可作为中晚期NSCLC的有效治疗方案。s:Objective To compare the short outcome of NVB (novelbine)plus DDP (cisplatin)regimen and EP(cisplatin and etoposide)regimen in the treatment of advanced non small cell cancer(NSCLC).Methods A total of 72 chemotherapy naive NSCLC patients were enrolled and randomly assigned to treatment group and control group.Two group were respectively treated with NVB plus DDP regimen and EP regimen for 2 cycles of chemotherapy.We evaluated ther esponse and side effect by WHO criteria.Results Response rate (CR+PR) is respectively 50 0% and 27 8%.The response rate of treatment group is higher than that of control group( P <0 05).Performence status of patients had been obviously improved in treatment group.The side effects in two group were different mainly in myelosupression and phlebitis.Serious leukopenia was respectively 55 6%and 16 7%.Phlebitis in 25 0% and 9 1%.The side effects in treatment group is more serious than that in control group( P <0 05).Conclusions NVB plus DDP regimen is a safe and effective chemotherapy regiment and may be a first line regimen for advanced NSCLC.

关 键 词：非小细胞肺癌 药物疗法 抗肿瘤 治疗 顺铂 足叶乙甙 异长春花碱 

分 类 号：R734.2[医药卫生—肿瘤]